

- Free T₄ index, 2288
 Free water deficit, 64e-4
 Freezing gait, 163, 165. *See also* Parkinson's disease
 Frenzel eyeglasses, 149
 Fresh-frozen plasma, 138e-2, 138e-2t, 736, 738, 739
 Friedreich's ataxia
 clinical features of, 451e-2t, 2629–2630
 genetic considerations in, 440t, 444e-9, 451e-2t, 1555t, 2630
 imaging in, 2629, 2629f
 SA node dysfunction in, 1467t
 treatment of, 2630
 Frontal abulic syndrome, 183–184
 Frontal bone fractures, 457e-2
 Frontal disinhibition syndrome, 183–184
 Frontal eye field, 209
 Frontal gait disorder, 163, 164t
 Frontal network syndrome, 184
 Frontotemporal dementia (FTD), **2602**
 ALS and, 2633
 behavioral variant, 183–184, 2603, 2603f
 clinical features of, 172, 173, 173t, 2602–2603
 functional anatomy of, 170
 genetic considerations in, 172t, 444e-1, 444e-9, 2603
 imaging in, 2603f
 molecular basis of, 172t
 nonfluent/agrammatic variant, 2603, 2603f
 pathogenesis of, 172t, 2603–2604, 2604f
 prions in, 453e-1
 semantic variant, 2603, 2603f
 syndromes
 corticobasal. *See* Corticobasal degeneration syndrome
 neuropathology of, 2604f
 in PD, 2605
 Pick's disease, 444e-8f, 2604, 2604f, 2605f
 progressive supranuclear palsy. *See* Progressive supranuclear palsy syndrome
 treatment of, 2604
 Frontotemporal lobar degeneration (FTLD), 2603–2604, 2604f
 Frostbite, **478e-3**
 clinical features of, 76e-5f, 478e-4, 478e-4f, 1648f, 1650
 pathophysiology of, 478e-4
 treatment of, 478e-4–5, 478e-4t, 1650
 Frostnip, 478e-4
 Frovatriptan, 2591, 2592t, 2593t
 "Frozen shoulder," 2249
 Fructose, 433e-1
 Fructose 1,6-biphosphate aldolase A deficiency, 433e-2t
 Fructose 1,6-biphosphate aldolase B deficiency, 433e-1f, 433e-3t, 433e-5
 Fructose 1,6-diphosphatase deficiency, 433e-1f, 433e-3t, 433e-5
 Fructose intolerance, hereditary, 433e-3t
 Fructose metabolism disorders, 433e-1f, 433e-3t, 433e-5
 Fructosuria, 433e-3t
 FSH. *See* Follicle-stimulating hormone (FSH)
 FSH β gene mutations, 2364, 2364t
 FSHD (facioscapulohumeral muscular dystrophy), 462e-1, 462e-2f, 462e-5t, 462e-11
 FSP. *See* Familial spastic paraplegia (FSP)
 FS (Functional Status) Score, 2668t
 FTA-ABS (fluorescent treponemal antibody-absorbed) test, 1137, 1137f
 FTC. *See* Emtricitabine (FTC)
 FTD. *See* Frontotemporal dementia (FTD)
 FTLD (frontotemporal lobar degeneration), 2603–2604, 2604f
 Fucosidosis, 432e-3t
 Fugue states, 2608
 Fukutin-related protein deficiency, 462e-9, 462e-10t
 Fukuyama congenital muscular dystrophy, 462e-9, 462e-10t
 Full liquid diet, 95e-5
 Fulvestrant, 530
 Fumagillin, 246e-4t, 246e-9
 Fumarate reductase, 246e-13
 Functional genomics, 426, 428
 Functional Independence Measure (FIM), 78t
 Functional MRI, 90f, 440e-8, 444e-12
 Functional redundancy, 86e-6
 Functional residual capacity (FRC), 306e-2, 306e-5f, 306e-6, 1733
 Functional somatic syndromes, 60e-2
 Functional status, 52t
 Functional Status (FS) Score, 2668t
 Fundoplication, 263, 1908
 Fundus, 40e-1
 in cardiovascular disease, 1443
 flat pigmented lesions of, 40e-6, 40e-6f, 40e-6t
 Fungal balls, 1347, 1348, 1349t
 Fungal infections, **1329**. *See also specific diseases*
 arthritis, 836
 in burn wounds, 166e-1, 166e-3
 in cancer patient, 491
 as cause of fever of unknown origin, 137t
 classification of, 1329
 diagnosis of, 1330
 endemic, 1329, 1329t
 epidemiology of, 1329
 infection control measures, 917
 mucocutaneous, 1357–1358, 1358t
 myocarditis, 1561
 opportunistic, 1329, 1329t, 1355–1357
 septic shock in, 781, 1752t
 terminology of, 1329
 in transplant recipient
 after HSCT, 920–921, 920t
 after solid organ transplant, 139e-4, 139e-4t, 926, 927, 1830–1831, 2072–2073
 treatment overview, 1330–1332. *See also specific drugs*
 Fungi
 adherence of, 145e-2t, 145e-3
 entry into host, 145e-1
 growth after entry, 145e-4
 in human microbiome, 86e-4
 laboratory evaluation of
 specimen collection and transport in, 150e-4t, 150e-5t
 specimen-processing algorithm for, 150e-6f
 staining in, 150e-2
 susceptibility testing in, 150e-8
 tissue invasion by, 145e-8, 145e-9
 Funnel chest (pectus excavatum), 1443, 2512
 Funnel-web spider, 2748
 FUO. *See* Fever of unknown origin (FUO)
 Furazolidone, 246e-4t, 246e-9
 Furosemide
 for acute kidney injury, 1810
 adverse effects of, 138, 322, 362, 379, 389t, 727t
 for ascites, 288, 2065
 for dyspnea, 47e-4
 for heart failure, 1510t, 1608
 for hypercalcemia of malignancy, 610
 for hypertension, 1624t
 for pulmonary edema, 62, 1761f, 1763
 for sepsis/septic shock, 1757
 for SIADH, 64e-5, 302, 610
 for uric acid nephropathy, 431e-5
 Furrier's lung, 1681t
 Furuncular myiasis, 2746
 Furunculosis, 228, 349
Fusarium spp., 1355
Fusarium spp. infections
 in cancer patient, 491
 clinical features of, 1356, 1356f
 diagnosis of, 1356
 epidemiology of, 1355–1356
 in transplant recipient, 920
 treatment of, 1356
 FUS gene mutations
 in ALS, 444e-1, 444e-9
 in essential tremor, 2619
 in frontotemporal dementia, 2603, 2604f
 Fusidic acid, 840t, 841t
 Fusiform aneurysm, 1637
Fusobacterium spp., 1094
Fusobacterium spp. infections. *See also*
 Anaerobic bacterial infections, mixed
 in cancer patient, 487
 in dog-bite wound, 167e-1
 in human bite-wounds, 167e-2
 infectious arthritis, 1100
 Lemierre's disease/syndrome. *See* Lemierre's disease/syndrome
 in lung abscess, 814
 peritonsillar abscess, 233
 pharyngitis, 231
 treatment of, 233
 FUS protein, 172t
 FUS/TLS gene, 2633, 2634t
 Futile care, 67, 1735
 FVC (forced vital capacity), 306e-5f, 306e-6
 F-wave studies, 442e-5
 FXR deficiency, 86e-9
 G
 G_{5a}, 2305t
 G6PC3 (glucose-6-phosphatase) deficiency, 375e-1
 G6PD deficiency. *See* Glucose-6-phosphate dehydrogenase (G6PD) deficiency
 G20210A mutation, 745
 GABA. *See* γ -aminobutyric acid (GABA)
 Gabapentin
 adverse effects of, 61, 2392, 2553t, 2682t
 for anxiety disorders, 2711
 for cluster headache prevention, 2595t
 for cough, 245
 for epilepsy, 2553t
 for fibromyalgia, 2240, 2240t
 for menopausal symptoms, 2383
 for migraine prevention, 2593
 for neuropathy, 61, 2682t
 for new daily persistent headache, 111
 overdosage/poisoning with, 473e-10t, 2765t
 for pain, 91t, 94, 2672
 for paroxysmal symptoms in MS, 2672
 pharmacology of, 2553t
 for restless legs syndrome, 192
 for SUNCT/SUNA prevention, 2596
 therapeutic monitoring of, 2765t
 GAD1 gene mutations, 465e-4
 GAD65 (glutamate decarboxylase), 372e-24t
 Gadolinium contrast, 270e-9, 379, 440e-5, 1819.
 See also Contrast agents
 Gadolinium exposure, 263e-3t
 gag gene, 225e-1, 225e-2, 225e-3f, 1218, 1219, 1219f
 Gag protein, 214e-5
 Gag reflex, 2538
 Gaisböck's syndrome, 400, 673
 Gait
 anatomy and physiology of, 162
 cerebellar, 616
 disorders, **162**
 approach to the patient, 164
 cautious gait, 163
 cerebellar ataxia, 163, 164t
 in elderly, 79–80, 80f
 etiology of, 162t
 freezing gait, 163, 165. *See also* Parkinson's disease
 frontal, 163, 164t
 in neuromuscular disease, 163–164
 psychogenic, 164
 sensory ataxia, 163, 164t
 stiff-legged, 163
 in toxic and metabolic disorders, 164
 video library, 33e-1v
 examination of, 2539
 Gait apraxia, 163
 Gait cycle, 162
 Galactokinase deficiency, 433e-1f, 433e-3t, 433e-5
 Galactomannan test, 1330, 1348
 Galactorrhea, 2267
 Galactose, 433e-1
 Galactose metabolism disorders, 433e-1f, 433e-3t, 433e-5